Veloxis Pharmaceuticals, part of Asahi Kasei Corporation, will present five posters at the American Transplant Congress in Boston from June 20 to 24, 2026. Three posters highlight real-world health economics and outcomes research, including comparisons of Envarsus XR versus immediate-release tacrolimus in adult liver transplant recipients and a survey on physician-patient symptom reporting discordance after kidney transplant. A post-hoc analysis examines concordance between C/D ratio and Cyp3A5 genotype in African American kidney transplant recipients on immediate-release tacrolimus. The fifth presentation covers a Phase 1 study of AIC468, a novel antisense oligonucleotide targeting BK virus, evaluating safety and pharmacokinetics in healthy volunteers and adult kidney transplant patients.
Asahi Kasei CorporationPresenting posters at a conference is a routine scientific activity; no clear positive or negative impact on Asahi Kasei's business.